Results 41 to 50 of about 116,988 (242)

PPARG is a potential target of Tanshinone IIA in prostate cancer treatment: a combination study of molecular docking and dynamic simulation based on transcriptomic bioinformatics

open access: yesEuropean Journal of Medical Research, 2023
Tanshinone IIA is a lipophilic organic compound from the root of Danshen (Salvia miltiorrhiza) and is one of the most well-known Tanshinone molecules by pharmacologists.
Tongtong Zhang   +7 more
doaj   +1 more source

Anti‐Inflammatory and Immunomodulatory Mechanism of Tanshinone IIA for Atherosclerosis [PDF]

open access: yesEvidence-Based Complementary and Alternative Medicine, 2014
Tanshinone IIA (Tan II A) is widely used in the treatment of cardiovascular diseases as an active component of Salvia miltiorrhiza Bunge. It has been demonstrated to have pleiotropic effects for atherosclerosis. From the anti‐inflammatory and immunomodulatory mechanism perspective, this paper reviewed major progresses of Tan IIA in antiatherosclerosis ...
Zhuo Chen, Hao Xu
openaire   +2 more sources

Analysis and Identification of Active Compounds from Salviae miltiorrhizae Radix Toxic to HCT-116 Human Colon Cancer Cells

open access: yesApplied Sciences, 2020
Colorectal cancer is one of the most frequently diagnosed cancers worldwide. The aim of the present study was to simultaneously analyze compounds of Salviae miltiorrhizae Radix (SMR) and determine their cytotoxic effects on HCT-116 human colorectal ...
Bohyung Kang   +4 more
doaj   +1 more source

Tanshinone IIA attenuates the stemness of breast cancer cells via targeting the miR-125b/STARD13 axis

open access: yesExperimental Hematology & Oncology, 2022
Background Tanshinone II A is an effective component extracted from Salvia miltiorrhiza and the roles of Tanshinone IIA in regulating the stemness of tumor cells remain unclear.
Xiaoman Li   +9 more
doaj   +1 more source

Prospective therapeutic potential of Tanshinone IIA: An updated overview

open access: yesPharmacological Research, 2021
In the past decades, the branch of complementary and alternative medicine based therapeutics has gained considerable attention worldwide. Pharmacological efficacy of various traditional medicinal plants, their products and/or product derivatives have been explored on an increasing scale. Tanshinone IIA (Tan IIA) is a pharmacologically active lipophilic
Mohammad Azam, Ansari   +9 more
openaire   +2 more sources

Simultaneous quantitative analyses of Tanshinone I, Cryptotanshinone, and Tanshinone IIA in Danshen (Salvia miltiorrhiza Bunge) cultivated in Vietnam using LC-MS/MS [PDF]

open access: yes, 2021
By using chromatography methods, the principal compounds tanshinon I, cryptotanshinone, tanshinone IIA were isolated from danshen (Salvia miltiorrhiza Bunge).
Trung, Van-Hoang ; Institute of Chemistry, Biology and Environment, Vinh University 460000, Vietnam   +6 more
core   +5 more sources

Effects of the coexisting diterpenoid tanshinones on the pharmacokinetics of cryptotanshinone and tanshinone IIA in rat

open access: yesEuropean Journal of Pharmaceutical Sciences, 2007
Tanshinone II(A) and cryptotanshinone are the main pharmacologically active components in the Chinese herb drug Salvia miltiorrhiza Bge. The objective of this study was to investigate the effect of coexisting tanshinones in liposoluble ethanol extract of S. miltiorrhiza Bge.
Min, Song   +3 more
openaire   +2 more sources

Salvia miltiorrhiza and Tanshinone IIA reduce endothelial inflammation and atherosclerotic plaque formation through inhibiting COX-2.

open access: yesBiomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2023
The mechanisms of Salvia miltiorrhiza (SM) and Tanshinone IIA (Tan IIA) in the treatment of atherosclerosis was examined by combining network pharmacology and molecular biology experiments.
Xiangke Ma   +4 more
semanticscholar   +1 more source

Efficacy of tanshinone IIA in rat models with myocardial ischemia–reperfusion injury: a systematic mini-review and meta-analysis [PDF]

open access: yesPeerJ
Background Myocardial ischemia–reperfusion injury (MIRI) refers to severe damage to the ischemic myocardium following the restoration of blood flow, and it is a major complication of reperfusion therapy for myocardial infarction.
Xiaobin Zhang   +9 more
doaj   +2 more sources

Tanshinone IIA enhances the therapeutic efficacy of mesenchymal stem cells derived exosomes in myocardial ischemia/reperfusion injury via up-regulating miR-223-5p.

open access: yesJournal of Controlled Release, 2023
Myocardial ischemia-reperfusion injury (MI/RI) is a serious obstacle for patients with coronary heart disease (CHD) to benefit from post-ischemic reflow.
Sheng Li   +10 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy